Investment Analysts’ Recent Ratings Changes for Allogene Therapeutics (ALLO)

Several brokerages have updated their recommendations and price targets on shares of Allogene Therapeutics (NASDAQ: ALLO) in the last few weeks:

• 3/19/2025 – Allogene Therapeutics had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a “buy” rating on the stock.
• 3/14/2025 – Allogene Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
• 3/14/2025 – Allogene Therapeutics was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $5.00 price target on the stock.
• 3/14/2025 – Allogene Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.

Allogene Therapeutics Stock Down 3.3 %

Shares of ALLO traded down $0.06 during midday trading on Wednesday, reaching $1.64. The company had a trading volume of 240,785 shares, compared to its average volume of 3,038,964. Allogene Therapeutics, Inc. has a 1-year low of $1.32 and a 1-year high of $4.63. The stock has a market cap of $342.81 million, a PE ratio of -1.05 and a beta of 1.02. The firm has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $2.30.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. As a group, sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the sale, the insider now owns 250,713 shares in the company, valued at $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,866 shares of company stock valued at $194,461. 24.30% of the stock is currently owned by insiders.

Institutional Trading of Allogene Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. abrdn plc purchased a new stake in Allogene Therapeutics during the fourth quarter worth about $776,000. Barclays PLC grew its position in shares of Allogene Therapeutics by 101.5% during the third quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after buying an additional 172,745 shares in the last quarter. Zacks Investment Management acquired a new position in shares of Allogene Therapeutics during the third quarter worth about $1,446,000. Geode Capital Management LLC grew its position in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after buying an additional 407,070 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its position in shares of Allogene Therapeutics by 788.4% during the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock worth $416,000 after buying an additional 173,457 shares in the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).